Canadian biotech company Generex has begun a study of its flagship
oral insulin spray in patients with Type-1 diabetes. The product,
already available for type 2 diabetes in Ecuador, was the first
non-injectable form of insulin to...
New insights into the dysregulation of beta cells and their impact
on type 2 diabetes progression is now possible after Roche
announced a partnership, which aims to identify novel pathways and
new biomarkers for drug development.
Generex Biotechnology announced its Oral-lyn, the first
non-injectable form of recombinant human insulin available for
commercial distribution anywhere in the world is being launched in
Ecuador to soon become available through physician...
Researchers are developing breakthrough diabetes drugs that use
modified forms of a naturally occurring molecule produced by the
body. The approach characterises the major investments by the
biopharmaceutical industry to develop and...
Sangamo BioSciences has initiated a Phase I clinical trial for its
novel therapy for diabetic neuropathy that is designed to protect
and stimulate the regeneration of peripheral nerve function in
diabetics suffering from peripheral...
US scientists have demonstrated that by knocking out two key
signals in liver cells causes diabetes. These findings pave the way
for drug strategies to boost these two different signals and treat
the different metabolic components...